Annotation Detail
Information
- Associated Genes
- ABCC3
- Associated Variants
-
ABCC3 AMPLIFICATION
(
ENST00000285238.13 )
ABCC3 AMPLIFICATION ( ENST00000285238.13 ) - Associated Disease
- breast cancer
- Source Database
- CIViC Evidence
- Description
- 44 cell lines and 145 patient samples were utilized in various aspects of this study. 31 breast cancer cell lines for in vitro sensitivity to paclitaxel and Monomethyl Auristatin E (MMAE). Genome wide amplification was assessed by Affymetrix SNP arrays and expression was assessed by Affymetrix gene expression arrays. ABCC3 amplification (and expression) in ERBB2 (HER2) amplified breast cancer cell lines was associated with resistance to paclitaxel and MMAE. Three independently derived EVSA-T cell lines overexpressing ABCC3 were at least 20-fold less sensitive to paclitaxel and MMAE based on EC50 values.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/951
- Gene URL
- https://civic.genome.wustl.edu/links/genes/6906
- Variant URL
- https://civic.genome.wustl.edu/links/variants/407
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Breast Cancer
- Evidence Direction
- Supports
- Drug
- Monomethyl Auristatin E,Paclitaxel
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 18593940
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Monomethyl Auristatin E | Resitance or Non-Reponse | true |
| Paclitaxel | Resitance or Non-Reponse | true |